Standout Papers

Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a ... 2017 2026 2020 2023 297
  1. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial (2017)
    Michele Maio, Arnaud Scherpereel et al. The Lancet Oncology

Immediate Impact

1 by Nobel laureates 9 from Science/Nature 59 standout
Sub-graph 1 of 22

Citing Papers

Advances in cancer immunotherapy: historical perspectives, current developments, and future directions
2025 Standout
Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
2024 Standout
1 intermediate paper

Works of M. Puglisi being referenced

Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial
2017 Standout

Author Peers

Author Last Decade Papers Cites
M. Puglisi 531 399 256 36 973
Mona Fouad 629 273 154 32 879
Christopher W. Lee 511 428 320 23 952
Gerard T. Kennealey 394 559 206 26 1.1k
Matteo Brighenti 610 305 177 38 839
Preston D. Steen 567 321 255 47 1.0k
Ho-Yeong Lim 342 301 295 31 850
M. Paganuzzi 321 508 252 37 970
Casey W. Williamson 364 201 296 30 894
Hiroki Ueda 635 304 110 56 889
Yeu‐Tsu N. Lee 609 338 155 56 1.0k

All Works

Loading papers...

Rankless by CCL
2026